TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15721570
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Attachment Based Family Therapy (ABFT)
Study: 8607621
Drug: Oral 5'-DFUR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5'-DFUR
Study: 8607621
Drug: Oral 5'-DFUR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5'-DFUR plus intratumor and intracutaneous OK-432
Study: 108804
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate inhalation solution
Study: 26744141
Drug: Fluoridated implants
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated implants in the maxilla
Study: 22897123
Drug: Mentalization-based psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based psychotherapy (MBT) for 2 years, twice weekly, combined individual and group therapy
Study: 22897123
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group therapy for 2 years, biweekly
Study: 21295639
Drug: Anesthesiologist-managed propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesiologist-managed propofol sedation (propofol infusion group)
Study: 11703246
Drug: Epidural patient-controlled
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural patient-controlled analgesia (PCA) using pethidine (bolus 10 mg, lockout interval 10 min, 4-h maximum dose 3 mg.kg(‐1))
Study: 11703246
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) using pethidine (bolus 10 mg, lockout interval 10 min, 4-h maximum dose 3 mg.kg(‐1))
Study: 10322828
Drug: Zhiganle capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhiganle capsule (ZGLC)
Study: 10322828
Drug: Dongbao Gantai
Normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dongbao Gantai (DBGT) tablets
Study: 8300840
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 micrograms orally (up to three doses)
Study: 8300840
Drug: Gemeprost vaginal
Normalized name: gemeprost
DrugBank: Gemeprost (DB08964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost vaginal pessary 1 mg (up to five doses)
Study: 29866947
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) of chemotherapy
Study: 21029638
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release tablets
Study: 18230966
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg x day(-1)
Study: 12915747
Drug: Almitrine 100
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 100 mg per day
Study: 11295661
Drug: Cetirizine, 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 0.25 mg/kg, twice daily for 18 months
Study: 11295661
Drug: Placebo, matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matching placebo twice daily for 18 months
Study: 9260417
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment for dental hard tissue
Study: 7684993
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (3 courses of the 'quick' VBP scheme)
Study: 15036674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no neoadjuvant chemotherapy)
Study: 31274211
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL normal saline (placebo)
Study: 27316324
Drug: Bedtime chronotherapy
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime chronotherapy with ≥1 conventional hypertension medications
Study: 25808497
Drug: Compression method
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression method (80-160 mL balloon volume)
Study: 25808497
Drug: Standard method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard method (50 mL balloon volume)
Study: 23931043
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum magnesium concentration (1.60‐2.50 mmol/L)
Study: 23931043
Drug: Normal serum
Normalized name: Albumin, Normal Serum, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal serum magnesium concentration (0.65‐1.05 mmol/L)
Study: 20099160
Drug: Viable Bifidobacterium
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viable Bifidobacterium supplement
Study: 14983963
Drug: Small focus
Normalized name: Ficus benghalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small focus of well-differentiated carcinoma on biopsy with serum PSA < 4 ng/mL
Study: 14983963
Drug: Small focus
Normalized name: Ficus benghalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small focus of well-differentiated carcinoma on biopsy with serum PSA >= 4 ng/mL
Study: 8714328
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of Events Scale administered to assess trauma impact
Study: 27191165
Drug: Deferiprone, 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone, 17 oral doses, supra-threshold concentrations (150 μM)
Study: 27191165
Drug: Deferiprone, 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone, 17 oral doses
Study: 23254592
Drug: Bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200 mg twice daily for 8 weeks)
Study: 18821287
Drug: Nandrolone phenpropionate
Normalized name: NANDROLONE PHENPROPIONATE
DrugBank: Nandrolone phenpropionate (DB00984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone phenpropionate (100 mg, intramuscularly, pulse-dose)
Study: 16018757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% sodium fluoride varnish and Nd:YAG laser
Study: 8540731
Drug: Levofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (200 mg) alone
Study: 1686184
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of riboflavin administered at night
Study: 7334934
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of oestriol succinate per day
Study: 7334934
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of oestriol succinate per day
Study: 7334934
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of oestriol succinate per day (divided into two doses)
Study: 25040143
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (pre‐emptive) received 0.125% ropivacaine 6 mL 30 min before skin incision and every 60 min during surgery, then PCEA.
Study: 25040143
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (routine) was given 0.125% ropivacaine 6 mL 30 min after surgery, then PCEA.
Study: 17875948
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation, 1 g capsule for 14 days
Study: 17875948
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g of corn oil)
Study: 9134786
Drug: Daily ratings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ratings of IBS symptoms for 8 weeks
Study: 3295019
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone treatment (200 mg t.i.d.)
Study: 17433577
Drug: Prebiotic formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic formula (0.4 g/100 ml prebiotic galacto- and long-chain fructooligosaccharides)
Study: 16965688
Drug: DLF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLF regimen (n=48): 2-hour infusion of folinic acid 200 mg/m(2), followed by 5-FU bolus 400 mg/m(2) and 48-hour infusion of 5-FU 3,000 mg/m(2) every 3 weeks, combined with cisplatin 80 mg/m(2)
Study: 16965688
Drug: CLF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLF regimen (n=32): 2-hour infusion of folinic acid 200 mg/m(2), followed by 5-FU bolus 400 mg/m(2) and 48-hour infusion of 5-FU 3,000 mg/m(2) every 3 weeks, combined with carboplatin AUC=5
Study: 16965688
Drug: DFM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFM regimen (n=18): 2-hour infusion of folinic acid 200 mg/m(2), followed by 5-FU bolus 400 mg/m(2) on day 1-5 plus pingyangmycin 5 mg/m(2) on day 1, 3, 5
Study: 12934407
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (Group B, n = 14)
Study: 12934407
Drug: Isoflurane-based inhalational-intravenous
Normalized name: isoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane-based inhalational-intravenous general anesthesia (Group C, n = 14)
Study: 10210912
Drug: nicergoline 30
Normalized name: nicergoline 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicergoline 30 mg b.i.d.
Study: 8726094
Drug: Beta‐adrenergic blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenergic blocking agents
Study: 8726094
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not on beta‐blockers
Study: 8726094
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on beta‐blockers
Study: 7811016
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg once daily)
Study: 1834010
Drug: Teicoplanin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (30 mg/kg once daily)
Study: 1834010
Drug: Teicoplanin and
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin and vancomycin in serum ultrafiltrate and SMHB at 60 micrograms/ml
Study: 30670099
Drug: Brief Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Group Psychoanalytic Psychotherapy (20 weeks, weekly sessions)
Study: 28881431
Drug: SmartXide Fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: SmartXide Fractional CO2 laser treatment
Study: 26179246
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg daily for 5 days every 4 weeks
Study: 8328549
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/day
Study: 24229360
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg 3 times a week
Study: 24080932
Drug: Reversible interocclusal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversible interocclusal splint therapy (RIST)
Study: 19366448
Drug: AS-SMP three-day
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-SMP three-day regimen (once daily for 3 days) (N = 476)
Study: 19366448
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) regular 6 doses regimen (N = 450)
Study: 19366448
Drug: AS-SMP three-day
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-SMP three-day regimen (once daily for 3 days)
Study: 19366448
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) regular 6 doses regimen
Study: 15265788
Drug: Intermediate-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose therapy (2 courses of melphalan at 100 mg/m(2) with stem cell support)
Study: 15265788
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (6 courses of oral melphalan and prednisone)
Study: 11297574
Drug: IGF-I treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I treatment (15 microg/kg twice daily)
Study: 11297574
Drug: IGF-I treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I treatment
Study: 9043536
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg atropine sulfate added to the first nebulizer and saline in the second and third treatments
Study: 9043536
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg atropine to the first and third treatments (with saline in the second)
Study: 9043536
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo during all 3 treatments
Study: 8196726
Drug: Cyclosporine (subsequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (subsequent treatment for placebo non-responders)
Study: 3286242
Drug: Fenugreek (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek (15 g) soaked in water
Study: 22622291
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg)
Study: 27208499
Drug: Subanesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)
Study: 24206741
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with levofloxacin, amoxicillin, and a PPI for 10 days
Study: 24206741
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with clarithromycin for 10 days
Study: 18513531
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg PO twice daily for a total of 14 doses (3 preoperative)
Study: 16579728
Drug: Grapefruit capsules
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit capsules
Study: 9208491
Drug: Combined drugs
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drugs (HPC + TMX, HPC + AG, TMX + AG)
Study: 7016089
Drug: Combined fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fluoride treatment (gel + rinse)
Study: 7016089
Drug: Gel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel treatment
Study: 7016089
Drug: Rinse treatment
Normalized name: Piperonyl Butoxide/Pyrethrum Extract 4%-0.33% Topical application Liquid [LICE CREME RINSE TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse treatment
Study: 26270587
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream applied to the forearm
Study: 16450373
Drug: Polyvalent, shed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent, shed antigen, melanoma vaccine
Study: 16873344
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 30 mL p.o. and saline 2 mL i.v.
Study: 16873344
Drug: Water 30
Normalized name: dextrose 30 % in water 30 % INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 30 mL p.o. and famotidine 20 mg i.v.
Study: 10193813
Drug: L‐NMMA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA treatment (3 mg/kg) after pretreatment with CAND (8 mg)
Study: 10193813
Drug: L‐NMMA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA treatment (3 mg/kg) after placebo
Study: 10193813
Drug: L‐NMMA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA treatment (3 mg/kg)
Study: 10451130
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg suppositories
Study: 7053160
Drug: Marihuana inhalation
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marihuana inhalation
Study: 25246239
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg), Vitamin E (400 mg), Zinc gluconate (25 mg), Selenomethionine (200 μg)
Study: 20963843
Drug: Biofilm testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofilm testing for antibiotic selection
Study: 18534087
Drug: Minocycline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 150 mg p.o. twice daily
Study: 12885990
Drug: Heterozygosity at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterozygosity at position 27 of the β2 adrenergic receptor (ADRB2) polymorphism
Study: 12885990
Drug: Polymorphism at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphism at position 16 of the β2 adrenergic receptor (ADRB2)
Study: 11789186
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CAKF plus chemotherapy)
Study: 11789186
Drug: Chemotherapy (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-FU and mitomycin C)
Study: 1892680
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide plus methylprednisolone (arm A)
Study: 1892680
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide plus methylprednisolone plus lorazepam (arm B)
Study: 6643694
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg dyphylline
Study: 6643694
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg dyphylline
Study: 6643694
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg dyphylline
Study: 6643694
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg anhydrous theophylline
Study: 31848050
Drug: Bivalent Oral
Normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent Oral Polio Vaccine (bOPV)
Study: 27455513
Drug: Levomilnacipran extended-release
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran extended-release (ER)
Study: 17241248
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine (Twinrix) administered at 0, 7, 21 to 30 days, and 12 months
Study: 17241248
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis B vaccine (Engerix-B) administered at 0, 1, 2, and 12 months
Study: 17241248
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis A vaccine (Havrix)
Study: 17241248
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis B vaccine (Engerix-B)
Study: 17241248
Drug: Monovalent vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccines (Havrix and Engerix-B)
Study: 15274701
Drug: Subcutaneous alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous alprostadil (low doses) with saline solution intravenously
Study: 15274701
Drug: Intravenous alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alprostadil with local saline solution injections
Study: 15274701
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution around the ulcers and intravenously (Control)
Study: 11526545
Drug: Entecavir 0.05
Normalized name: entecavir 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.05 mg
Study: 21513847
Drug: Entecavir 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.1 mg
Study: 21513847
Drug: Entecavir 1.0
Normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1.0 mg
Study: 9248873
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg twice a day, doubled after 3 weeks if needed)
Study: 9248873
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg q.a.m., doubled after 3 weeks if needed)
Study: 30558092
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric ropivacaine (15.2 mg) with 5 μg sufentanil
Study: 30558092
Drug: Prophylactic infusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusion of phenylephrine (50 μg/min)
Study: 27433861
Drug: Hypertrophic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertrophic resistance training (RT) for 6 weeks, two 40-minute sessions weekly, three sets of 12 repetitions at 67% to 85% one-repetition maximum for 10 whole-body exercises.
Study: 22990352
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg/day)
Study: 22990352
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy (further diuretic and other drugs)
Study: 22990352
Drug: No-add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-add-on therapy